• Dendritic cells (DC) for cancer immunotherapy protocols are generated most commonly by in vitro differentiation of monocytes with exogenous cytokines (Mo-DC). (nih.gov)
  • antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. (trialx.com)
  • Her research integrates issues of In vitro, Cytokine and Follicular dendritic cells in her study of Cell biology. (research.com)
  • OBJECTIVE: The role of plasmacytoid dendritic cells (PDCs) and type I interferons (IFNs) in rheumatoid arthritis (RA) remains a subject of controversy. (cnrs.fr)
  • Nevertheless, ex vivo activation with cytokines can restore cytolytic activity of NK cells against GB, indicating that NK cells have potential for adoptive immunotherapy of GB if potent cytotoxicity can be maintained in vivo . (frontiersin.org)
  • NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. (frontiersin.org)
  • Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. (frontiersin.org)
  • We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients. (frontiersin.org)
  • Unlike chemotherapy or radiation which directly attack tumors, immunotherapy helps train the immune cells to recognize markers on cancer cells and boosts their killing capability. (theusaknowledge.net)
  • By binding to these antigens, monoclonal antibodies can flag cancer cells for destruction by the immune system. (theusaknowledge.net)
  • Dendritic cells are key antigen-presenting cells of the immune system. (theusaknowledge.net)
  • This approach involves isolating patient's dendritic cells, loading them with tumor antigens and reinfusing to induce a wider immune reaction. (theusaknowledge.net)
  • Adoptive cell transfer involves engineering patient's own T-cells to create receptors on their surface that recognize specific tumor antigens. (theusaknowledge.net)
  • Monoclonal antibodies bind to target proteins on cancer cells, flagging them for destruction. (theusaknowledge.net)
  • By targeting these critical regulators of immune response to cancer, immunotherapies augment the natural defenses of the body to attack malignant cells across multiple pathways. (theusaknowledge.net)
  • Adoptive transfer of immature myeloid cells lacking p50 (p50-IMC) slows the growth of syngeneic murine prostate cancer, pancreatic ductal carcinoma, or neuroblastoma when given after a dose of myelo-depleting 5-fluorouracil. (bmj.com)
  • 1 2 p50-IMC develop into tumor macrophages and dendritic cells and induce increased total and activated tumor T cells. (bmj.com)
  • We now evaluate whether we can enhance wild-type (WT) or p50-IMC tumor localization and/or the phagocytosis of PSMA+ prostate cancer cells by expressing a prostate-specific membrane antigen (PSMA)-specific chimeric antigen receptor (CAR) on IMC, or by combining IMC with PSMA antibody (Ab), which binds to the surface of myeloid cells via their Fc receptors. (bmj.com)
  • Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma. (bmj.com)
  • This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. (nshealth.ca)
  • Histopathological analyses showed increased infiltration of dendritic cells (DC) and T cells into tumor tissues following 7 × 19 CAR-T cell therapy. (nature.com)
  • Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients with Locoregional Nasopharyngeal Carcinoma. (texaschildrens.org)
  • This work represents a novel approach for cancer immunotherapy by integrating nanotechnology and platinum-based therapeutics which not only efficiently exerts the chemotherapeutic cytotoxic effect on tumor cell but also restores immune response of immunological cells within the tumor microenvironment. (thno.org)
  • For example, antibodies specific to tumor antigens, adoptively transferred immune cells, therapeutic vaccines, and recombinant cytokines effectively boost the host immune system to recognize tumor cells as pathogens and eliminate them [ 1 - 3 ]. (thno.org)
  • One study reported an increased survival benefit with simultaneous RT compared with sequential administration, 8 while another study found no significant difference between the two strategies, 9 possibly because simultaneous RT plus immunotherapy and the administration of an ICI before RT may kill cancer cells as well a substantial number of immune cells, leading to poor systemic response and toxic side effects. (nature.com)
  • Of note, the TME is rich in immunosuppressive cells (e.g., tumor-associated macrophages (TAMs), regulatory T cells (Tregs), immature dendritic cells (iDCs) and myeloid-derived suppressor cells (MDSCs)), that can suppress antitumor immunity as a result of secretion of various cytokines and chemokines, which enables tumor escape from immune surveillance [ 8 ]. (thno.org)
  • Among most immunosuppressive cells, TAMs, as crucial drivers of immunosuppressive TME, account for the largest proportion of immune cells in the TME (approximately 50% of tumor mass) [ 9 , 10 ], which possess highly heterogeneity and play a complex regulatory role in tumor immunity and immunotherapy due to helping tumor evade immune surveillance [ 11 ]. (thno.org)
  • IL-2 is expressed by CD4+ and CD8+ T cells, gamma δ T cells, B cells, dendritic cells, and eosinophils (1-3). (rndsystems.com)
  • Other current efforts include the exploration of immunomodulation to potentiate endogenous antitumor T cell responses, use of bispecific antibodies, pharmacological sensitization of tumor cells to immune attack, tumor vasculature targeting, preclinical validations, clinical translation and trial support. (upenn.edu)
  • Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. (biomedcentral.com)
  • Flow cytometry analysis of CD19 was performed by staining Raji CD19 Knock out cells with 0.25 µg Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™ (Product # 12-4714-82, yellow histogram) or 0.25 µg CD19 Monoclonal Antibody (HIB19), PE, eBioscience™ (Product # 12-0199-42, blue histogram). (thermofisher.com)
  • Follicular dendritic cells also express CD19. (thermofisher.com)
  • Applications Tested: This HIB19 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. (thermofisher.com)
  • Chen J, Wang S, Jia S, Ding G, Jiang G, Cao L. Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. (jcancer.org)
  • Dendritic cells (DCs), which are the most potent antigen-presenting cells in the human body, play a pivotal role in the immune response. (jcancer.org)
  • The expression profiles of long noncoding RNAs (lncRNAs) and mRNAs of PEX-treated dendritic cells are unknown. (jcancer.org)
  • Converting an Anti-Mouse CD4 Monoclonal Antibody into an scFv Positron Emission Tomography Imaging Agent for Longitudinal Monitoring of CD4(+) T Cells. (amedeo.com)
  • A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells. (amedeo.com)
  • Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity. (amedeo.com)
  • In this study, we tested whether preventative and therapeutic vaccination could be achieved by direct injection of antigen-expressing lentiviral vector, obviating the need for ex vivo transduction of dendritic cells. (jci.org)
  • Injected lentiviral vector preferentially transduced splenic dendritic cells and resulted in long-term expression. (jci.org)
  • To the contrast, while the emerging immunotherapy focus on stimulating the immune system to awake the vital specific and active auto-immunocyte to be able to be targeting on attacking and destroying the remaining cancer cells after surgery to result a much better efficacy in longer life and living quality of a patient after receiving a radiotherapy or chemotherapy. (safesavecell.com)
  • The way of Passive Immunity is to have patients receive allogeneic antibodies in order to inhibit the cancer cells metastasis or to kill the cancer cells. (safesavecell.com)
  • Despite of various types of immunocyte in human body, the most frequent applied in current cancer immunotherapy is NK, Natural Killer Cells, the one and the only one specific cell, T cells and Dendritic Cells, DCs shows the best antigen presenting ability, etc. (safesavecell.com)
  • Dendritic cells originate in human hematopoietic stem cells within bones marrow, the differentiation process begins with the stem cells differentiate into bone marrow precursor cells, then mononuclear and eventually dendritic cells. (safesavecell.com)
  • Autologous Dendritic Cell/ Tumor Antigen" ADCTA cancer immunotherapy is a tailor made cancer treatment takes original autologous cancer antigens and immunocyte from the patient, ADCTA is exactly precise and suitable for every individual patient compared with chemotherapy or target therapeutic drugs which is designed based on a generic characters of cancer cells. (safesavecell.com)
  • Consistent with in vitro observations, in mice with PD-L1-deficient MC38 colorectal tumors where only host cells were the source of PD-L1, antibody blockade of both PD-1/PD-L1 and PD-L1/B7-1 interactions reduced tumor growth, while blocking only PD-L1/B7-1 interactions slightly accelerated tumor growth due to an increased availability of PD-L1. (acir.org)
  • Analysis of the tumor-infiltrating myeloid populations at days 3, 7, and 14 post tumor inoculation revealed that the majority of myeloid cells were macrophages, which far outnumbered cross-presenting dendritic cells (DCs). (acir.org)
  • Natural antibodies are produced by B cells to target and bind to specific cell-surface antigens. (immunogenetics.com)
  • The antibodies then direct other immune cells to attack cells containing the antigen. (immunogenetics.com)
  • Most are referred to as passive immunotherapies because they directly bind to cancer cells. (immunogenetics.com)
  • Others act as active immunotherapies because they target immune cells as well, and help them find cancer cells. (immunogenetics.com)
  • Antibody-drug conjugates are antibodies that carry a chemotherapy drug or radioactive particle, and deliver these toxic substances directly to the cancer cells. (immunogenetics.com)
  • Also known as cellular immunotherapy, adoptive cell therapy uses T cells to fight cancer. (immunogenetics.com)
  • Dendritic cells are an essential component of the immune system. (medicalxpress.com)
  • To produce the vaccine, the researchers engineered the patients' own dendritic cells to express survivin and induce an immune response against the protein. (medicalxpress.com)
  • To increase the number of survivin peptides presented to the immune system, and therefore the likelihood of triggering a survivin-specific response, Locke and team engineered the dendritic cells to express a version of the entire protein, with a mutation to increase safety without compromising immunogenicity. (medicalxpress.com)
  • Clinically, EBV-associated malignancies such as Hodgkin's lymphoma offer a unique model to explore antigen-defined immunotherapy approaches because EBV-derived tumor antigens are specific for tumor cells only. (dukecancerinstitute.org)
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
  • Patient PBMCs are collected by leukapheresis followed by enrichment approaches to isolate T cells while removing other cells such as B cells, monocytes, neutrophils, dendritic cells and contaminating tumor cells. (bdbiosciences.com)
  • CiMaas announced the granting of a European Patent on its Dendritic Cells maturation technology, an essential part of its Dendritic Cell Vaccine Product. (cimaas.com)
  • CiMaas has signed an agreement with London-based Cancer Research Technology, the commercial arm of the charity Cancer Research UK, and the University of Copenhagen under which CiMaas will test a proprietary monoclonal antibody in combination with natural killer cells for the treatment of cancer. (cimaas.com)
  • Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic And/or Locally Recurrent Nasopharyngeal Carcinoma. (texaschildrens.org)
  • As one of the four major means of cancer treatment including surgery, radiotherapy (RT), chemotherapy, immunotherapy, RT can be applied to various cancers as both a radical cancer treatment and an adjuvant treatment before or after surgery. (nature.com)
  • The emergence of immunotherapy has recently disrupted the paradigm of traditional cancer treatment (including the three traditional treatments RT, chemotherapy, and surgery), and immunotherapy functions by activating the body's immune system to fight cancer. (nature.com)
  • Three months later, when a recurrence-suspected lesion was detected in segment 5 (S5) of his liver, we started adoptive immunotherapies with cytokine-activated killer (CAK) cell infusions, combined with chemotherapy. (springeropen.com)
  • We report here a rare case of a patient who has currently survived almost 10 years with recurrent GBC with peritoneal dissemination and liver metastases, which has been well controlled by a multidisciplinary approach including chemotherapy, immunotherapy, and surgery. (springeropen.com)
  • Among with 3 conventional treatments of surgery, radiotherapy and chemotherapy, the public worldwide has very high expectation ever since to consider the immunotherapy to be the 4th treatment on the list of options. (safesavecell.com)
  • Reports of spontaneous regression and tumour infiltration with T-lymphocytes makes melanoma candidate for immunotherapies. (mdpi.com)
  • CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. (amedeo.com)
  • IL-1alpha Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. (amedeo.com)
  • Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen-4 (CTLA-4). (biomedcentral.com)
  • Description: The HIB19 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein. (thermofisher.com)
  • Description: The BC96 monoclonal antibody reacts with human CD25, the 55 kDa interleukin-2 receptor alpha chain (IL-2Ralpha). (thermofisher.com)
  • Multiple Myeloma on CureTalks in 2017: CAR T Cell Immunotherapy, Stem Cell Transplants, MRD Testing, MMRF Precision Medicine Model and More. (trialx.com)
  • Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. (trialx.com)
  • We talked to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. (trialx.com)
  • A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma, according to research published in Clinical Cancer Research . (medicalxpress.com)
  • Multiple myeloma is a chronic and incurable cancer," said Frederick L. Locke, MD, chair of the Blood and Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center and senior author of the study. (medicalxpress.com)
  • Locke and colleagues designed a dendritic cell vaccine targeting a protein called survivin and tested this vaccine in a phase I clinical trial involving 13 patients with multiple myeloma. (medicalxpress.com)
  • CiMaas recently applied for a classification for its' Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. (cimaas.com)
  • Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.This brings CiMaas again a step closer to fund its' development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer. (cimaas.com)
  • New strategies such as monoclonal antibody therapies. (trialx.com)
  • Unfortunately, many patients still progress and acquire resistance to immunotherapy and molecularly targeted therapies. (biomedcentral.com)
  • Furthermore, the treatment landscape for myeloma is rapidly evolving, with new-generation therapies such as CAR T-cell therapy and bispecific antibodies being tested before transplant. (medicalxpress.com)
  • In this blog, we explore the different types of immunotherapies, their mechanisms of action, current uses in cancer treatment, limitations, and the exciting future possibilities of this transformative therapy. (theusaknowledge.net)
  • There are various types of immunotherapies used to treat cancer today, and still more being developed and used in clinical trials. (immunogenetics.com)
  • Immunotherapy mainly includes immune checkpoint inhibitors (ICIs), such as inhibitors of PD-1 (programmed cell death 1)/programmed cell death ligand 1 (PD-L1). (nature.com)
  • New model systems are being developed to test and optimize various immunotherapy strategies, including bispecific antibodies, checkpoint inhibitors, epigenetic modifiers and adoptive T cell transfer both in vitro and in vivo. (upenn.edu)
  • An unusual and modern treatment has been created, especially for stage 4 GBM, using the latest therapeutic techniques, including immunotherapy and virotherapy. (bvsalud.org)
  • Thus, TAMs can be considered as a promising therapeutic target for improved immunotherapy, and TAMs-focused molecular targeting agents have made ideal progress in clinical practice. (thno.org)
  • It is hoped that, with rapid development of nanomedicine in cancer immunotherapy, TAMs-focused therapeutic strategies may be anticipated to become an emerging immunotherapeutic modality for future clinical cancer treatment. (thno.org)
  • Immunotherapy is currently considered as a promising next-generation therapeutic strategy for various cancers thanks to its ability to modulate cell-specific immune responses toward tumors [ 1 ], which has gradually remodeled the landscape of clinical anticancer modality [ 2 ]. (thno.org)
  • Combination with other immunotherapy regimens improve overall therapeutic efficacy. (biomedcentral.com)
  • Lentiviral vector-based dendritic cell vaccines induce protective T cell responses against viral infection and cancer in animal models. (jci.org)
  • Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses. (pipelinereview.com)
  • IL-2 and IFN-γ), immune checkpoint blockade (ICB) therapy (e.g., anti-PD-1/PD-L1 antibodies), and adoptive T-cell transfer (e.g., chimeric antigen receptor (CAR) T-cell therapy) [ 3 - 5 ]. (thno.org)
  • Antibody-AdV complexes can provoke inflammatory cytokine and chemokine responses in macrophages via the intracellular antibody receptor TRIM21 [56-59]. (genemedi.com)
  • Our scientific fraternity achieved a lot this year in the field of cancer treatment, giving new ray of hope to cancer patients with advances in immunotherapy, stem cell transplants and genomic testing. (trialx.com)
  • Despite significant recent improvements in the field of immunotherapy, cancer remains a heavy burden on patients and healthcare systems. (mdpi.com)
  • A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-ΔLMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal Carcinoma. (texaschildrens.org)
  • Enhancing the in Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients. (texaschildrens.org)
  • These data confirm the presence of tumor-specific TCR within the cancer tissue and suggest the existence of shared epitopes among different patients that might be used as targets for tumor immunotherapy. (oncotarget.com)
  • In this situation, immunotherapy could be a reliable candidate to improve the prognosis of these patients without lowering their quality of life. (springeropen.com)
  • It uses human's tumor debris, synthetic peptide drugs or applying the adoptive immunotherapy to increase the patients' immunity. (safesavecell.com)
  • Dendritic cell vaccines have the potential to harness the patients ' own immune system to get them into remission and potentially keep the cancer from coming back. (medicalxpress.com)
  • Antibodies against survivin peptides were detected in two out of 13 patients at baseline and nine out of 13 patients after vaccination and ASCT. (medicalxpress.com)
  • Overall, 85% of patients had either a T-cell response or an antibody response against survivin," said Locke. (medicalxpress.com)
  • Karolina Palucka mostly deals with Immunology, Immune system, Dendritic cell, Cancer and Cancer research. (research.com)
  • With a better understanding of molecular details in tumor immunology and tumor biology, tailored cancer immunotherapy is considered as a promising strategy for cancer treatment. (thno.org)
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • Her work deals with themes such as Neuroscience and Cytokine, which intersect with Dendritic cell. (research.com)
  • In clinical practice, cancer immunotherapies have been well developed in recent years, mainly including cytokine therapy (e.g. (thno.org)
  • The XMG1.2 monoclonal antibody reacts with mouse IFNγ (interferon gamma) a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. (bioxcell.com)
  • Immune-inflamed tumors are called hot tumors, while the latter two are collectively referred to as cold tumors, and they respond poorly to immunotherapy. (nature.com)
  • Wei X, Wang J, Liang M, Song M. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. (thno.org)
  • Clinical cancer immunotherapies are usually impeded by tumor immunosuppression driven by tumor associated macrophages (TAMs). (thno.org)
  • Moreover, TAMs usually display M2-like phenotypes that exert tumor-promoting role in TME, and promote production of related immunosuppressive factors that trigger immunotherapy resistance, including cytokines, chemokines, growth factors and soluble signaling mediators [ 12 ]. (thno.org)
  • These properties have made lentiviral vectors advantageous for use in dendritic cell (DC) vaccines. (jci.org)
  • In recent years, immunotherapies have led to remarkable strides in treating certain cancers. (mdpi.com)
  • After decades of research, immunotherapy has now emerged as a revolutionary approach against certain types of cancers. (theusaknowledge.net)
  • Multidisciplinary approach including immunotherapy for such cancers has received much attention in recent years. (springeropen.com)
  • A major requirement for cancer immunotherapy is the development of biomarkers for prognosis and for monitoring therapy response. (oncotarget.com)
  • This included sessions dedicated to systems biology on immunotherapy, immunogenicity and gene expression profiling, biomarkers, and combination treatment strategies. (biomedcentral.com)
  • To bypass resistance, combination treatment with immunotherapies and single or multiple TKIs have been shown to improve prognosis compared to monotherapy. (biomedcentral.com)
  • Cardiovascular immunotherapy has therefore become a recent focus for treatment, with the objective to develop approaches that can suppress excessive inflammatory responses by modulating specific immune cell populations. (frontiersin.org)
  • FM-depots therefore present a customizable delivery platform to both develop and test nanomedicine-based approaches for anti-inflammatory cardiovascular immunotherapy. (frontiersin.org)
  • Cancer immunotherapy approaches designed to surmount tumor suppression take into consideration the pivotal molecular processes involved in the activation of immune system. (thno.org)
  • Her Immunotherapy research is multidisciplinary, incorporating elements of Blockade, Adoptive cell transfer and Sarcoma. (research.com)
  • Immunotherapy may be a promising modality among multidisciplinary methods for advanced cancer. (springeropen.com)
  • Innate lymphoid cell is closely connected to Antigen-presenting cell in her research, which is encompassed under the umbrella topic of Dendritic cell. (research.com)
  • Her Immunotherapy research focuses on Adoptive cell transfer and how it connects with Cell, Cancer, Monoclonal antibody, Antibody and Blockade. (research.com)
  • Her Immunity study combines topics in areas such as Cancer cell, Blockade, Antigen, Cell biology and Immunotherapy. (research.com)
  • PD-1 axis blockade has been proven time and again to be a successful immunotherapy for a wide variety of cancer types, and it is assumed to work by reversing or preventing T cell exhaustion. (acir.org)
  • However, the exact way by which this cancer immunotherapy works has not been fully elucidated, and recent studies have shown that the mechanism behind PD-1 axis blockade may be more complex than previously thought. (acir.org)
  • This Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated. (thermofisher.com)
  • NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. (bmj.com)